Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Very difficult to be constructive

<< Previous

Bullboard Posts

Next >>

Comment by Scioto1on Mar 02, 2022 1:28pm

104 Views

Post# 34475711

RE:RE:RE:RE:RE:RE:RE:RE:RE:Very difficult to be constructive

If you read through my thread you'll see that I acknowledge that our clinical work and project development is critical. But I think it's Also an important responsibility of management to engage shareholders, engage potential institutional investors, engage analysts, and advance a public information campaign plan all with an eye towards shareholder value. I'm not talking about creating it out of thin air. It needs to be an important priority just like the research and development.

<< Previous

Bullboard Posts

Next >>

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity